company background image
A175250 logo

Icure Pharmaceutical Incorporation KOSDAQ:A175250 Stock Report

Last Price

₩2.11k

Market Cap

₩78.9b

7D

-15.4%

1Y

-19.2%

Updated

01 Sep, 2024

Data

Company Financials

Icure Pharmaceutical Incorporation

KOSDAQ:A175250 Stock Report

Market Cap: ₩78.9b

A175250 Stock Overview

A biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea.

A175250 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Icure Pharmaceutical Incorporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Icure Pharmaceutical Incorporation
Historical stock prices
Current Share Price₩2,110.00
52 Week High₩3,490.00
52 Week Low₩1,775.00
Beta0
11 Month Change-26.86%
3 Month Change-8.46%
1 Year Change-19.16%
33 Year Change-88.08%
5 Year Change-74.79%
Change since IPO-89.97%

Recent News & Updates

Recent updates

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

Aug 28
Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Jul 21
What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

May 31
Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

May 27
Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

Mar 07
Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

Dec 25
We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

Shareholder Returns

A175250KR Personal ProductsKR Market
7D-15.4%0.5%-1.0%
1Y-19.2%-10.1%1.0%

Return vs Industry: A175250 underperformed the KR Personal Products industry which returned -10.1% over the past year.

Return vs Market: A175250 underperformed the KR Market which returned 1% over the past year.

Price Volatility

Is A175250's price volatile compared to industry and market?
A175250 volatility
A175250 Average Weekly Movement12.0%
Personal Products Industry Average Movement8.0%
Market Average Movement6.5%
10% most volatile stocks in KR Market12.1%
10% least volatile stocks in KR Market3.4%

Stable Share Price: A175250's share price has been volatile over the past 3 months.

Volatility Over Time: A175250's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2000202n/awww.icure.co.kr

Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks.

Icure Pharmaceutical Incorporation Fundamentals Summary

How do Icure Pharmaceutical Incorporation's earnings and revenue compare to its market cap?
A175250 fundamental statistics
Market cap₩78.85b
Earnings (TTM)-₩23.89b
Revenue (TTM)₩59.84b

1.3x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A175250 income statement (TTM)
Revenue₩59.84b
Cost of Revenue₩54.85b
Gross Profit₩4.99b
Other Expenses₩28.88b
Earnings-₩23.89b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-639.22
Gross Margin8.34%
Net Profit Margin-39.92%
Debt/Equity Ratio141.2%

How did A175250 perform over the long term?

See historical performance and comparison